Skip to content
Pompe Disease News logo
  • About Pompe
    What is Pompe disease?
    Types
    Symptoms
    Causes
    Diagnosis
    Treatment options
    • Lumizyme
    • Nexviazyme
    • Pombiliti + Opfolda
  • News
  • Columns
    Powering Through Pompe — Keara Engle
    Archived columns
    • The Pompe Community Diaries – Anthony Wu
    • On the Road to Pompe — Dwayne Wilson
  • Featured topics
    Living with Pompe
    • Pompe service dog
    • Adaptive clothing
    • Living with Pompe disease
    • ERT and enzyme stabilizers
    • The ERT process
    • Your daily routine with LOPD
    • Adaptive equipment
    • Late-onset Pompe disease
    • Dwayne’s story
    • Expert voice: Safe and effective exercise
    • View all
    Pompe pathways
    • ERT home infusions
    • Therapeutic crossroads
    • Tips for caregivers
    • Maximizing doctor’s appointments
    • Building an LOPD care team
    • Financial planning with Pompe
    • Work and Pompe
    • Occupational therapy
    • Pompe and pain
  • FAQs
  • Advocacy partners
  • What can we help you find today?

February 22, 2022 News by Marta Figueiredo, PhD

First Healthy Volunteers Dosed in Trial of Oral Therapy MZE001

The first healthy volunteers have been dosed in a Phase 1 clinical trial evaluating MZE001, Maze Therapeutics’ experimental oral therapy for Pompe disease. “The initiation of this study is a significant milestone for both Maze and the Pompe community as we advance into the clinic with a potentially…

January 11, 2022 News by Marisa Wexler, MS

Maze Raises $190M, Gears Up for First Clinical Testing of MZE001

Maze Therapeutics has announced its plans to begin clinical testing of MZE001, its lead candidate therapy for Pompe disease, in the first half of this year. The California-based precision medicine company raised $190 million in financing — led by Matrix Capital Management — to support the development of…

Recent Posts

  • Myozyme may help LOPD patients walk, breathe over long term
  • Genetic test flags Pompe disease in expectant father with no symptoms
  • COL13A1 gene levels may link to Pompe neuromuscular dysfunction


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.